Radioactive iodine (RAI) treatment is used in patients with thyroid cancer to treat disease and to eradicate normal thyroid remnants. Routine post-operative administration of RAI is no longer indicated in patients with low risk thyroid cancer and might instead be used selectively in patients with a post-operative high serum level of thyroglobulin.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Mazzaferri, E. L. & Jhiang, S. M. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am. J. Med. 97, 418–428 (1994).
Pasqual, E. et al. Trends in the management of localized papillary thyroid carcinoma in the united states (2000–2018). Thyroid 32, 397–410 (2022).
Mallick, U. et al. Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. N. Engl. J. Med. 366, 1674–1685 (2012).
Schlumberger, M. et al. Strategies of radioiodine ablation in patients with low-risk thyroid cancer. N. Engl. J. Med. 366, 1663–1673 (2012).
Schlumberger, M. et al. Outcome after ablation in patients with low-risk thyroid cancer (ESTIMABL1): 5-year follow-up results of a randomised, phase 3, equivalence trial. Lancet Diabetes Endocrinol. 6, 618–626 (2018).
Dehbi, H. M. et al. Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial. Lancet Diabetes Endocrinol. 7, 44–51 (2019).
Lamartina, L., Durante, C., Filetti, S. & Cooper, D. S. Low-risk differentiated thyroid cancer and radioiodine remnant ablation: a systematic review of the literature. J. Clin. Endocrinol. Metab. 100, 1748–1761 (2015).
Chou, R. et al. Serum thyroglobulin measurement following surgery without radioactive iodine for differentiated thyroid cancer: a systematic review. Thyroid https://doi.org/10.1089/thy.2021.0666 (2022).
Nascimento, C. et al. Persistent disease and recurrence in differentiated thyroid cancer patients with undetectable postoperative stimulated thyroglobulin level. Endocr. Relat. Cancer 18, R29–R40 (2011).
Leboulleux, S. et al. Thyroidectomy without Radioiodine in Patients with Low-Risk Thyroid Cancer. N. Engl. J. Med. 386, 923–932 (2022).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Related links
Pathological tumour-node-metastasis: https://www.uicc.org/resources/tnm
Supplementary information
Rights and permissions
About this article
Cite this article
Leboulleux, S., Borget, I. & Schlumberger, M. Post-operative radioactive iodine administration in patients with low-risk thyroid cancer. Nat Rev Endocrinol 18, 585–586 (2022). https://doi.org/10.1038/s41574-022-00709-z
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41574-022-00709-z